HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
diprafenone
structure given in first source
Networked:
7
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Ketones: 2618
Propiophenones: 1
Propafenone: 787
diprafenone: 7
Related Diseases
1.
Body Weight (Weight, Body)
12/01/1986 - "
Electrophysiologic studies were performed before and after intravenous infusion of 1.5 mg/kg body weight diprafenone in a period of 10 minutes.
"
03/01/1989 - "
The effect of intravenous (1.5 to 2.0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia.
"
2.
Premature Cardiac Complexes (Extrasystoles)
07/01/1988 - "
In a randomized study, we analyzed the antiarrhythmic efficacy and tolerance of diprafenone (450-600 mg/day) in comparison to that of propafenone (450-500 mg/day) in ten patients with frequent and complex ventricular premature beats.
"
3.
Ventricular Tachycardia
12/01/1986 - "
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
"
01/01/1985 - "
In additional 16 animals the effects of diprafenone on "delayed" reperfusion arrhythmias following release of coronary artery occlusion after 2 h and on stimulus-induced ventricular tachycardia in acute myocardial infarction were investigated.
"
07/01/1987 - "
Diprafenone can be considered an effective antiarrhythmic drug for the treatment of supraventricular and ventricular tachyarrhythmias.
"
12/01/1986 - "
The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia).
"
4.
Wolff-Parkinson-White Syndrome (Wolf-Parkinson-White Syndrome)
03/01/1989 - "
Diprafenone for treatment of Wolff-Parkinson-White syndrome.
"
03/01/1989 - "
The effect of intravenous (1.5 to 2.0 mg/kg body weight) and oral (300 to 375 mg/d) diprafenone was studied in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia.
"
12/01/1986 - "
The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia).
"
5.
Tachycardia (Tachyarrhythmias)
04/01/1989 - "
Diprafenone caused the loops of the end-systolic pressure-volume relationship to move rightward and decreased the slope k, indicating negative entropy, both at rest and during tachycardia.
"
04/01/1989 - "
Left ventricular volumes increased under the influence of diprafenone, both at rest (end-diastolic volume by an average of 12%, end-systolic volume by 21%) and during tachycardia (by 15% and by 47%, respectively).
"
04/01/1989 - "
Thirteen patients underwent hemodynamic analysis with and without the influence of diprafenone 1.5 mg/kg, both a) at rest (paced heart rate of 90 beats/min and b) during tachycardia (paced tachycardia of 160 beats/min).
"
04/01/1989 - "
Diprafenone induced a depression of left ventricular function during tachycardia only: Ejection fraction fell by an average of 25% and stroke work by 19%, while end-diastolic pressure increased by an average of 28% and systemic vascular resistance by 34%.
"
03/01/1989 - "
Intravenous diprafenone suppressed the inducibility of supraventricular tachycardia in two patients, but the tachycardia cycle length was significantly increased in all other patients.
"
Related Drugs and Biologics
1.
Propafenone (Rythmol)
2.
Anti-Arrhythmia Agents
Related Therapies and Procedures
1.
Intravenous Infusions
2.
Therapeutics